About this Research Topic
Over the last two decades, the prevalence of obesity has significantly increased. It has been considered as a part of the metabolic syndrome and seems to induce a chronic inflammatory reaction in the human body, which has been involved in the pathophysiology of several gastrointestinal (GI) cance types, such as esophageal cancer, gastric cancer, colon cancer and hepatobiliary cancer. Accumulation of fatty tissue leads to increased triglycerides (TGs) and low-density lipoproteins (LDL), as well as remarkable tissue resistance to insulin. On the other hand, hyperinsulinemia has been proposed as a possible part of the metabolic pathway of oncogenesis. Finally, obesity induces the production of pre-inflammatory cytokines and hormones from the adipose tissue, such as adipokines, which play a key role in the metabolic cascade of oncogenesis.
The main goal of this Research Topic is to present the available information about possible correlations between obesity-associated hormones and different cancer types in the GI tract. In addition, new data about relationships between obesity-associated cytokines and oncologic outcomes of GI cancers could be demonstrated. This would highlight the pathophysiologic mechanisms through which obesity mediates oncogenesis in the GI tract. Therefore, the predictive value of different obesity-associated cytokines and hormones regarding oncologic outcomes of GI cancer patients could be evaluated. Finally, new therapeutic targets would be investigated in order to achieve a prompt treatment of patients with early diagnosed GI tumors.
All future contributors are welcome to provide their work on “Obesity and Gastrointestinal Cancer” based on high scientific standards and strict methodology. Narrative reviews, cohort trials, systematic reviews and meta-analyses regarding the association of different obesity-related hormones and cytokines with different types of gastrointestinal cancer types are kindly invited. The role of specific biomarkers such as fatty acids, triglycerides (TGs), low-density lipoproteins (LDL), insulin, pro-inflammatory factors (interleukin-6, tumor necrosis factor-α) and hormones (leptin, adipokine) on predicting oncologic outcomes of esophageal cancer, gastric cancer, colon cancer and hepatobiliary cancer should be investigated. Finally, any possible therapeutic contribution of these biomarkers against GI cancers should be demonstrated.
We would like to acknowledge Mrs Irene Lidoriki who has acted as Research Topic Coordinator and has contributed to the preparation of the proposal for this Research Topic.
The main goal of this Research Topic is to present the available information about possible correlations between obesity-associated hormones and different cancer types in the GI tract. In addition, new data about relationships between obesity-associated cytokines and oncologic outcomes of GI cancers could be demonstrated. This would highlight the pathophysiologic mechanisms through which obesity mediates oncogenesis in the GI tract. Therefore, the predictive value of different obesity-associated cytokines and hormones regarding oncologic outcomes of GI cancer patients could be evaluated. Finally, new therapeutic targets would be investigated in order to achieve a prompt treatment of patients with early diagnosed GI tumors.
All future contributors are welcome to provide their work on “Obesity and Gastrointestinal Cancer” based on high scientific standards and strict methodology. Narrative reviews, cohort trials, systematic reviews and meta-analyses regarding the association of different obesity-related hormones and cytokines with different types of gastrointestinal cancer types are kindly invited. The role of specific biomarkers such as fatty acids, triglycerides (TGs), low-density lipoproteins (LDL), insulin, pro-inflammatory factors (interleukin-6, tumor necrosis factor-α) and hormones (leptin, adipokine) on predicting oncologic outcomes of esophageal cancer, gastric cancer, colon cancer and hepatobiliary cancer should be investigated. Finally, any possible therapeutic contribution of these biomarkers against GI cancers should be demonstrated.
We would like to acknowledge Mrs Irene Lidoriki who has acted as Research Topic Coordinator and has contributed to the preparation of the proposal for this Research Topic.
Keywords: obesity, metabolic syndrome, gastrointestinal, tract, esophageal, gastric, pancreatic, liver, biliary, colorectal, cancer
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
